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Tuberculosis is the global health burden and the conventional therapies are unable to deliver 
the drug to the alveolar macrophages, where the causative agent (Mycobacterium 
tuberculosis) resides and replicates. The potential of chitosan polymer conjugated with 
hyaluronic acid was exploited for the targeted drug delivery via inhalation [1]. Nano mediated 
drug delivery vehicle was synthesized using ionic gelation for the active targeting of the 
alveolar macrophages. Dry powder inhalers (DPI) comprised of biodegradable polymeric 
nanocarriers with adequate aerodynamic profile, drug release and biocompatibility is a major 
challenge for pulmonary drug delivery. Quality by design approach was therefore employed 
to critically evaluate the risk assessment profile to enhance the product optimization [2]. 
Physicochemical tests including FT-IR, DSC, TGA, XRPD, SEM, size analyses and aerodynamic 
characterization provided useful data about compatibility and stability of the nanoparticular 
system. Nano DPI might hence improve the drug bioavailability by the reduction in dosing 
frequency and toxicity [3]. 
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